Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound
Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) single-dose vials for obesity treatment. Through LillyDirect, Ro will provide patients with streamlined access to this FDA-approved medication at a self-pay price,
Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...
It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
Eli Lilly partners with telehealth company Ro to distribute discounted Zepbound vials at $399/month, while competitor Novo ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback